These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Excellence of quipazine in the characterization of serotoninergic receptors and mechanisms]. Hong E Gac Med Mex; 1982 Apr; 118(4):158-64. PubMed ID: 7117731 [No Abstract] [Full Text] [Related]
5. Activation of serotonin2 (5-HT2) receptors by quipazine increases arterial pressure and renin secretion in conscious rats. Alper RH; Snider JM J Pharmacol Exp Ther; 1987 Dec; 243(3):829-33. PubMed ID: 3320345 [TBL] [Abstract][Full Text] [Related]
6. Antagonism of 5-hydroxytryptamine receptors by quipazine. Lansdown MJ; Nash HL; Preston PR; Wallis DI; Williams RG Br J Pharmacol; 1980 Mar; 68(3):525-32. PubMed ID: 7052342 [TBL] [Abstract][Full Text] [Related]
8. Effects of quipazine on pre- and postsynaptic serotonin receptors: single cell studies in the rat CNS. Blier P; de Montigny C Neuropharmacology; 1983 Apr; 22(4):495-9. PubMed ID: 6856049 [TBL] [Abstract][Full Text] [Related]
9. [Comparative anorexigenic activity and other pharmacological properties of quipazine and its N-acyl derivatives]. Trubitsyna TK; Asnina VV; Mashkovskiĭ MD Farmakol Toksikol; 1986; 49(1):44-9. PubMed ID: 3948987 [TBL] [Abstract][Full Text] [Related]
10. On the role of the central serotoninergic system in the regulation of the secretion of thyrotropin and prolactin: thyrotropin-inhibiting and prolactin-releasing effects of 5-hydroxytryptamine and quipazine in the male rat. Krulich L; Vijayan E; Coppings RJ; Giachetti A; McCann SM; Mayfield MA Endocrinology; 1979 Jul; 105(1):276-83. PubMed ID: 446410 [No Abstract] [Full Text] [Related]
11. Quipazine-induced stimulus control in the rat. Winter JC Psychopharmacology (Berl); 1979 Feb; 60(3):265-9. PubMed ID: 108704 [No Abstract] [Full Text] [Related]
12. [Quipazine antagonizing baclofen activity. Influence of baclofen and gamma-hydroxybutyric acid on serotonin metabolism in rat brain (author's transl)]. Waldmeier PC; Maître L Arzneimittelforschung; 1978; 28(9):1507-8. PubMed ID: 582544 [TBL] [Abstract][Full Text] [Related]
14. The actions of neuroleptic drugs and putative serotonin receptor antagonists on LSD and quipazine-induced reductions of brain 5-HIAA concentrations. Jacoby JH; Poulakos JJ J Pharm Pharmacol; 1977 Dec; 29(12):771-3. PubMed ID: 22629 [No Abstract] [Full Text] [Related]
15. Quipazine induced wet dog shake behaviour in rats: mechanism of action. Hiremagalur ; Keshavan JH; Dandiya PC; Gurbani NK Pharmacol Res Commun; 1980 Sep; 12(8):757-68. PubMed ID: 6160597 [No Abstract] [Full Text] [Related]
16. A serotonin agonist-antagonist reversible effect on Na+-K+-ATPase activity in the developing rat brain. Hernández RJ Dev Neurosci; 1982; 5(4):326-31. PubMed ID: 6291893 [TBL] [Abstract][Full Text] [Related]
18. Sleep suppressant action of quipazine: relation to central serotonergic stimulation. Fornal C; Radulovacki M Pharmacol Biochem Behav; 1981 Dec; 15(6):937-44. PubMed ID: 7323120 [TBL] [Abstract][Full Text] [Related]
19. Serotonin-induced head shaking behavior in rats does not involve receptors located in the frontal cortex. Lucki I; Minugh-Purvis N Brain Res; 1987 Sep; 420(2):403-6. PubMed ID: 2960422 [TBL] [Abstract][Full Text] [Related]
20. Effect of chronic administration of fenfluramine and quipazine on body weight gain after ovariectomy and on brain serotonin receptor binding. Rowland N; Carlton J; Bartness T; Smith G Behav Neurosci; 1983 Jun; 97(3):502-5. PubMed ID: 6683563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]